COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

LCS12 Adolescent Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01434160
Recruitment Status : Completed
First Posted : September 14, 2011
Last Update Posted : July 27, 2015
Information provided by (Responsible Party):

Brief Summary:

The study will assess the safety of a sex hormone (levonorgestrel) releasing T-shaped intrauterine contraceptive system in female adolescents under 18 years of age. Approximately 300 generally healthy, post-menarcheal female adolescents with regular menses at the beginning of the study requiring contraception will be enrolled into the study.

Duration of study treatment is approximately 12 months with an option to continue the use of the contraceptive system up to three years if the woman is willing to continue the use after the first 12 months.

The incidence of adverse events over 12 month treatment period will be the main outcome of this study. Also the efficacy (number of pregnancies), discontinuation rate and pharmacokinetics will be evaluated.

Condition or disease Intervention/treatment Phase
Contraception Drug: Skyla (Levonorgestrel, BAY86-5028) Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 304 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Multi-center, Single-arm Study to Assess the Safety, Efficacy, Discontinuation Rate and Pharmacokinetics of the Low-dose Levonorgestrel Intrauterine Contraceptive System (LCS12) in Post-menarcheal Female Adolescents Under 18 Years of Age for 1 Year, and an Optional 2-year Extension Phase
Study Start Date : September 2011
Actual Primary Completion Date : June 2013
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Birth Control

Arm Intervention/treatment
Experimental: Arm 1 Drug: Skyla (Levonorgestrel, BAY86-5028)
Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.

Primary Outcome Measures :
  1. Number of adverse events reported by study subjects [ Time Frame: 12 months treatment period ]
  2. Portion of subjects reporting adverse events [ Time Frame: 12 months treatment period ]

Secondary Outcome Measures :
  1. Overall satisfaction rating from 1 to 5 (from very satisfied to very dissatisfied) [ Time Frame: 12 months treatment period ]
  2. Pearl index [ Time Frame: 12 months treatment period ]
  3. Bleeding patterns collected from patients' diary [ Time Frame: 12 months treatment period ]
  4. Concentration of Levonorgestrel in serum [ Time Frame: At 1, 3, 6, 9 or 12 months ]
  5. Concentration of sex hormone binding globulin in serum [ Time Frame: At 1, 3, 6, 9 or 12 months ]
  6. Discontinuation rate [ Time Frame: 12 months treatment period ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • The subject has signed and dated the informed consent form (ICF)
  • The subject is female, generally healthy, post-menarcheal, nulliparous or parous, requiring contraception, and is under 18 years of age at the Screening visit
  • The subject has regular menstrual cycles without hormonal contraceptive use (at regular intervals of 21-35 days)
  • In the opinion of the investigator, the subject has general and uterine conditions suitable for the insertion of levonorgestrel intrauterine contraceptive system (LCS12) (uterine sound depth 6-10 cm)
  • Has clinically normal safety laboratory results
  • The subject has a normal or clinically insignificant cervical smear (i.e. one that does not require further follow up according to Bethesda or a comparable system)
  • The subject is willing and able to attend the scheduled study visits and to comply with the study procedures

Exclusion Criteria:

  • Known or suspected pregnancy or is lactating
  • Vaginal delivery, cesarean delivery, or abortion less than 6 weeks before Visit 1
  • History of ectopic pregnancies
  • Infected abortion or postpartum endometritis less than 3 months before Visit 1
  • Abnormal uterine bleeding of unknown origin
  • Any lower genital tract infection (until successfully treated)
  • Acute or history of recurrent pelvic inflammatory disease
  • Congenital or acquired uterine anomaly

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01434160

Layout table for location information
St. Pölten, Niederösterreich, Austria, 3100
Bregenz, Austria, 6900
Voitsberg, Austria, 8570
Wien, Austria, 1070
Zeltweg, Austria, 8740
Antwerpen, Belgium, 2018
Bruxelles - Brussel, Belgium, 1020
Bruxelles - Brussel, Belgium, 1090
Charleroi, Belgium, 6000
Leuven, Belgium, 3000
København NV, Denmark, DK-2400
København S, Denmark, 2300
Århus C, Denmark, DK-8000
Helsinki, Finland, 00100
Helsinki, Finland, 00610
Kuopio, Finland, 70110
Oulu, Finland, 90100
Oulu, Finland, 90220
Erlangen, Bayern, Germany, 91054
Geseke, Nordrhein-Westfalen, Germany, 59590
Köln, Nordrhein-Westfalen, Germany, 50931
Blankenburg, Sachsen-Anhalt, Germany, 38889
Dippoldiswalde, Sachsen, Germany, 01744
Dresden, Sachsen, Germany, 01169
Leipzig, Sachsen, Germany, 04207
Leipzig, Sachsen, Germany, 04299
Hamburg, Germany, 21073
Hamburg, Germany, 22587
Alkmaar, Netherlands, 1817 MS
Almere, Netherlands
Den Helder, Netherlands, 1780 AT
Enschede, Netherlands
Heerlen, Netherlands
Nieuwegein, Netherlands, 3435 CM
Tilburg, Netherlands
Fornebu, Norway, 1364
Sellebakk, Norway, 1653
Göteborg, Sweden, 411 18
Stockholm, Sweden, 118 83
Stockholm, Sweden, 171 76
Uppsala, Sweden, 75185
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01434160    
Other Study ID Numbers: 14371
2011-002065-37 ( EudraCT Number )
First Posted: September 14, 2011    Key Record Dates
Last Update Posted: July 27, 2015
Last Verified: July 2015
Keywords provided by Bayer:
Additional relevant MeSH terms:
Layout table for MeSH terms
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral